Morgan Stanley Trims AMAG Pharmaceuticals, Inc. (AMAG) Target Price to $22.00

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) had its target price cut by analysts at Morgan Stanley from $26.00 to $22.00 in a research report issued to clients and investors on Friday, November 3rd. The firm presently has an “overweight” rating on the specialty pharmaceutical company’s stock. Morgan Stanley’s price target indicates a potential upside of 52.25% from the company’s previous close.

Other analysts have also issued reports about the stock. BidaskClub upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Piper Jaffray Companies began coverage on shares of AMAG Pharmaceuticals in a research note on Monday, October 23rd. They issued a “neutral” rating and a $18.00 price target for the company. Citigroup Inc. reduced their price target on shares of AMAG Pharmaceuticals to $24.00 and set a “hold” rating for the company in a research note on Friday, July 7th. Zacks Investment Research lowered shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 26th. Finally, Cowen and Company reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Thursday, August 10th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $24.00.

AMAG Pharmaceuticals (NASDAQ AMAG) traded up $0.40 during midday trading on Friday, reaching $14.45. The company’s stock had a trading volume of 978,000 shares, compared to its average volume of 1,125,797. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59. AMAG Pharmaceuticals has a one year low of $11.93 and a one year high of $36.83.

ILLEGAL ACTIVITY WARNING: This article was originally published by Week Herald and is the property of of Week Herald. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://weekherald.com/2017/11/14/morgan-stanley-lowers-amag-pharmaceuticals-inc-amag-price-target-to-22-00.html.

Several institutional investors have recently added to or reduced their stakes in AMAG. State of Alaska Department of Revenue raised its position in shares of AMAG Pharmaceuticals by 81.3% during the second quarter. State of Alaska Department of Revenue now owns 6,871 shares of the specialty pharmaceutical company’s stock valued at $126,000 after buying an additional 3,081 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its position in shares of AMAG Pharmaceuticals by 6.6% during the second quarter. Municipal Employees Retirement System of Michigan now owns 8,280 shares of the specialty pharmaceutical company’s stock valued at $152,000 after buying an additional 510 shares during the last quarter. Hartford Investment Management Co. bought a new stake in shares of AMAG Pharmaceuticals during the third quarter valued at approximately $186,000. 361 Capital LLC bought a new stake in shares of AMAG Pharmaceuticals during the third quarter valued at approximately $197,000. Finally, Aperio Group LLC bought a new stake in shares of AMAG Pharmaceuticals during the third quarter valued at approximately $198,000.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply